Gurpreet Arora1,2, Arun Gupta2, Tong Guo1, Aakash Gandhi3, Aaron Laine2, Dorothy Williams3, Chul Ahn4, Puneeth Iyengar2,4, Rodney Infante1,3,4,5. 1. Department of Molecular Genetics, University of Texas (UT) Southwestern Medical Center, Dallas, Texas, USA. 2. Department of Radiation Oncology, University of Texas (UT) Southwestern Medical Center, Dallas, Texas, USA. 3. Center for Human Nutrition, University of Texas (UT) Southwestern Medical Center, Dallas, Texas, USA. 4. Harold C. Simmons Comprehensive Cancer Center, University of Texas (UT) Southwestern Medical Center, Dallas, Texas, USA. 5. Department of Internal Medicine, University of Texas (UT) Southwestern Medical Center, Dallas, Texas, USA.
Abstract
BACKGROUND: Cachexia, a syndrome of muscle atrophy, adipose loss, and anorexia, is associated with reduced survival in cancer patients. The colon adenocarcinoma C26c20 cell line secretes the cytokine leukemia inhibitory factor (LIF) which induces cachexia. We characterized how LIF promotes cachexia-associated weight loss and anorexia in mice through JAK-dependent changes in adipose and hypothalamic tissues. METHODS: Cachexia was induced in vivo with the heterotopic allotransplanted administration of C26c20 colon adenocarcinoma cells or the intraperitoneal administration of recombinant LIF in the absence or presence of JAK inhibitors. Blood, adipose, and hypothalamic tissues were collected and processed for cyto/adipokine ELISAs, immunoblot analysis, and quantitative RT-PCR. Cachexia-associated lipolysis was induced in vitro by stimulating differentiated adipocytes with recombinant LIF or IL-6 in the absence or presence of lipase or JAK inhibitors. These adipocytes were processed for glycerol release into the media, immunoblot analysis, and RT-PCR. RESULTS: Tumor-secreted LIF induced changes in adipose tissue expression and serum levels of IL-6 and leptin in a JAK-dependent manner influencing cachexia-associated adipose wasting and anorexia. We identified two JAK inhibitors that block IL-6 family-mediated adipocyte lipolysis and IL-6 induction using an in vitro cachexia lipolysis assay. JAK inhibitors administered to the in vivo C26c20 cancer cachexia mouse models led to 1) a decrease in STAT3 phosphorylation in hypothalamic and adipose tissues, 2) a reverse in the cachexia serum cyto/adipokine signature, 3) a delay in cancer cachexia-associated anorexia and adipose loss, and 4) an improvement in overall survival. CONCLUSIONS: JAK inhibitors suppress LIF-associated adipose loss and anorexia in both in vitro and in vivo models of cancer cachexia.
BACKGROUND: Cachexia, a syndrome of muscle atrophy, adipose loss, and anorexia, is associated with reduced survival in cancer patients. The colon adenocarcinoma C26c20 cell line secretes the cytokine leukemia inhibitory factor (LIF) which induces cachexia. We characterized how LIF promotes cachexia-associated weight loss and anorexia in mice through JAK-dependent changes in adipose and hypothalamic tissues. METHODS: Cachexia was induced in vivo with the heterotopic allotransplanted administration of C26c20 colon adenocarcinoma cells or the intraperitoneal administration of recombinant LIF in the absence or presence of JAK inhibitors. Blood, adipose, and hypothalamic tissues were collected and processed for cyto/adipokine ELISAs, immunoblot analysis, and quantitative RT-PCR. Cachexia-associated lipolysis was induced in vitro by stimulating differentiated adipocytes with recombinant LIF or IL-6 in the absence or presence of lipase or JAK inhibitors. These adipocytes were processed for glycerol release into the media, immunoblot analysis, and RT-PCR. RESULTS: Tumor-secreted LIF induced changes in adipose tissue expression and serum levels of IL-6 and leptin in a JAK-dependent manner influencing cachexia-associated adipose wasting and anorexia. We identified two JAK inhibitors that block IL-6 family-mediated adipocyte lipolysis and IL-6 induction using an in vitro cachexia lipolysis assay. JAK inhibitors administered to the in vivo C26c20 cancer cachexia mouse models led to 1) a decrease in STAT3 phosphorylation in hypothalamic and adipose tissues, 2) a reverse in the cachexia serum cyto/adipokine signature, 3) a delay in cancer cachexia-associated anorexia and adipose loss, and 4) an improvement in overall survival. CONCLUSIONS: JAK inhibitors suppress LIF-associated adipose loss and anorexia in both in vitro and in vivo models of cancer cachexia.
Authors: Katharina Timper; Jesse Lee Denson; Sophie Marie Steculorum; Christian Heilinger; Linda Engström-Ruud; Claudia Maria Wunderlich; Stefan Rose-John; F Thomas Wunderlich; Jens Claus Brüning Journal: Cell Rep Date: 2017-04-11 Impact factor: 9.423
Authors: Samuele M Marcora; Kathryn R Chester; Gayatri Mittal; Andrew B Lemmey; Peter J Maddison Journal: Am J Clin Nutr Date: 2006-12 Impact factor: 7.045
Authors: Steven K M Lau; Bhavani S Gannavarapu; Kristen Carter; Ang Gao; Chul Ahn; Jeffrey J Meyer; David J Sher; Aminah Jatoi; Rodney Infante; Puneeth Iyengar Journal: J Oncol Pract Date: 2018-03-20 Impact factor: 3.840
Authors: Shangang Zhao; Yi Zhu; Robbie D Schultz; Na Li; Zhenyan He; Zhuzhen Zhang; Alexandre Caron; Qingzhang Zhu; Kai Sun; Wei Xiong; Hui Deng; Jia Sun; Yingfeng Deng; Min Kim; Charlotte E Lee; Ruth Gordillo; Tiemin Liu; Angela K Odle; Gwen V Childs; Ningyan Zhang; Christine M Kusminski; Joel K Elmquist; Kevin W Williams; Zhiqiang An; Philipp E Scherer Journal: Cell Metab Date: 2019-09-05 Impact factor: 27.287
Authors: Jennifer S Temel; Amy P Abernethy; David C Currow; John Friend; Elizabeth M Duus; Ying Yan; Kenneth C Fearon Journal: Lancet Oncol Date: 2016-02-20 Impact factor: 41.316
Authors: Sarah H Bates; Walter H Stearns; Trevor A Dundon; Markus Schubert; Annette W K Tso; Yongping Wang; Alexander S Banks; Hugh J Lavery; Asma K Haq; Eleftheria Maratos-Flier; Benjamin G Neel; Michael W Schwartz; Martin G Myers Journal: Nature Date: 2003-02-20 Impact factor: 49.962
Authors: Nicole E Rich; Samuel Phen; Nirali Desai; Sukul Mittal; Adam C Yopp; Ju Dong Yang; Jorge A Marrero; Puneeth Iyengar; Rodney E Infante; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2021-09-20 Impact factor: 13.576